Treats chronic idiopathic constipation (CIC). ANDA 218963, held by Appco. Prucalopride Succinate.
As of Nov 16, 2026, ANDA 218963 (Prucalopride Succinate), held by Appco, was first approved by FDA on Jun 24, 2025, with 0 approved supplements and 0 published complete response letters.
Prucalopride tablets are indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 24, 2025 | Original application | Approved | None posted |
| Prucalopride SuccinateEQ 1MG BASE · tablet;oral | Prucalopride Succinate | Rx |
| Prucalopride SuccinateEQ 2MG BASE · tablet;oral | Prucalopride Succinate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters